Pharming Promises and risks of biopharmaceuticals derived from genetically modified plants and animals /

Recent scientific advances have made it possible to produce biopharmaceuticals in genetically modified plants and animals, such as maize, tobacco, goats, and chickens. This new branch of biotechnology is termed pharming, composed of the terms pharmaceuticals and farming. Pharming constitutes an over...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Rehbinder, Eckard (Συγγραφέας), Rehbinder, E. (Συγγραφέας), Engelhard, M. (Συγγραφέας), Hagen, K. (Συγγραφέας), Jørgensen, R. B. (Συγγραφέας), Pardo-Avellaneda, R. (Συγγραφέας), Schnieke, A. (Συγγραφέας), Thiele, F. (Συγγραφέας)
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Berlin, Heidelberg : Springer Berlin Heidelberg, 2009.
Σειρά:Ethics of Science and Technology Assessment, Schriftenreihe der Europäischen Akademie zur Erforschung von Folgen wissenschaftlich-technischer Entwicklungen Bad Neuenahr-Ahrweiler GmbH, 35
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 04359nam a22005895i 4500
001 978-3-540-85793-8
003 DE-He213
005 20151204165254.0
007 cr nn 008mamaa
008 100301s2009 gw | s |||| 0|eng d
020 |a 9783540857938  |9 978-3-540-85793-8 
024 7 |a 10.1007/978-3-540-85793-8  |2 doi 
040 |d GrThAP 
050 4 |a RM1-950 
072 7 |a MMG  |2 bicssc 
072 7 |a MED071000  |2 bisacsh 
082 0 4 |a 615  |2 23 
100 1 |a Rehbinder, Eckard.  |e author. 
245 1 0 |a Pharming  |h [electronic resource] :  |b Promises and risks of biopharmaceuticals derived from genetically modified plants and animals /  |c by Eckard Rehbinder, E. Rehbinder, M. Engelhard, K. Hagen, R. B. Jørgensen, R. Pardo-Avellaneda, A. Schnieke, F. Thiele. 
264 1 |a Berlin, Heidelberg :  |b Springer Berlin Heidelberg,  |c 2009. 
300 |a XX, 334 p.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a Ethics of Science and Technology Assessment, Schriftenreihe der Europäischen Akademie zur Erforschung von Folgen wissenschaftlich-technischer Entwicklungen Bad Neuenahr-Ahrweiler GmbH,  |x 1860-4803 ;  |v 35 
505 0 |a The technology of pharming -- Risk assessment of plant pharming and animal pharming -- The welfare of pharming animals -- Public views and attitudes to pharming -- The ethical evaluation of pharming -- The role of patents in the development of pharming -- Legal problems of pharming -- Conclusions and recommendations. 
520 |a Recent scientific advances have made it possible to produce biopharmaceuticals in genetically modified plants and animals, such as maize, tobacco, goats, and chickens. This new branch of biotechnology is termed pharming, composed of the terms pharmaceuticals and farming. Pharming constitutes an overlap of red and green biotechnology. It offers the prospect of a quicker, cheaper, and more flexible production of biopharmaceuticals compared with current production processes. This is a promising perspective in light of the rapidly growing market of biopharmaceuticals, although the economic competitiveness of pharming remains to be proven. Besides possible benefits for producers, patients and health care systems, pharming also raises a number of complex ecological, social, moral and legal questions that have as yet not been thoroughly discussed. The present book contains the findings of an interdisciplinary research project that has addressed a large range of questions associated with pharming: An analysis of the state-of-the-art of plant pharming and animal pharming technologies is followed by an assessment of environmental risks related to pharming and welfare risks for pharming animals. Public views and attitudes to pharming are investigated on the basis of a comprehensive survey in 15 countries. Moreover, ethical and legal questions, posed by present and foreseeable future practices of pharming, are analysed. The concluding chapter presents the authors’ main findings and recommendations, addressed to science, industry, politics and general public interested in the chances and risks of this upcoming field of biotechnology. 
650 0 |a Medicine. 
650 0 |a Pharmacology. 
650 0 |a Biochemical engineering. 
650 0 |a Ethics. 
650 0 |a Biomedical engineering. 
650 1 4 |a Biomedicine. 
650 2 4 |a Pharmacology/Toxicology. 
650 2 4 |a Biochemical Engineering. 
650 2 4 |a Ethics. 
650 2 4 |a Biomedical Engineering. 
700 1 |a Rehbinder, E.  |e author. 
700 1 |a Engelhard, M.  |e author. 
700 1 |a Hagen, K.  |e author. 
700 1 |a Jørgensen, R. B.  |e author. 
700 1 |a Pardo-Avellaneda, R.  |e author. 
700 1 |a Schnieke, A.  |e author. 
700 1 |a Thiele, F.  |e author. 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9783540857921 
830 0 |a Ethics of Science and Technology Assessment, Schriftenreihe der Europäischen Akademie zur Erforschung von Folgen wissenschaftlich-technischer Entwicklungen Bad Neuenahr-Ahrweiler GmbH,  |x 1860-4803 ;  |v 35 
856 4 0 |u http://dx.doi.org/10.1007/978-3-540-85793-8  |z Full Text via HEAL-Link 
912 |a ZDB-2-SBL 
950 |a Biomedical and Life Sciences (Springer-11642)